Ultimovacs Q3 2023: Sights set on INITIUM top-line data in H1 2024e - Redeye

Redeye comments on Ultimovacs’ Q3 2023 report, with recently presented NIPU survival data paving UV1’s path to phase III trials in mesothelioma. All eyes are now set on INITIUM top-line data, set for communication in March or April 2024e. We do some housekeeping in our model and adjust our valuation.

Länk till analysen i sin helhet: https://www.redeye.se/research/956893/ultimovacs-q3-2023-sights-set-on-initium-top-line-data-in-h1-2024e?utm_source=finwire&utm_medium=RSS